MaxCyte
MXCT
123 hedge funds and large institutions have $281M invested in MaxCyte in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 47 reducing their positions, and 12 closing their positions.
80% more call options, than puts
Call options by funds: $18K | Put options by funds: $10K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
3% more funds holding
Funds holding: 120 → 123 (+3)
3.69% less ownership
Funds ownership: 67.91% → 64.22% (-3.7%)
13% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 47
15% less capital invested
Capital invested by funds: $331M → $281M (-$50M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$5.82M |
| 2 |
Millennium Management
New York
|
+$5.44M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$4.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.89M |
| 5 |
MA
Mudita Advisors
London,
United Kingdom
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.2M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$6.71M |
| 3 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$6.01M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$4.86M |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
-$1.91M |
MXCT Hedge Fund Activity: Q1 2024 in Review
123 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q1 2024, worth a combined $281M — down 15% from $331M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MXCT positions and 12 closed out — a net gain of 3 holders — while 41 added to existing stakes and 47 trimmed.
The largest buyer was Chevy Chase Trust, adding an estimated $5.82M. The largest seller was Morgan Stanley, cutting an estimated $16.2M.
- 123 institutional investors held MaxCyte (MXCT) as of Q1 2024, up from 120 in Q4 2023.
- Funds reported $281M of MaxCyte stock for Q1 2024, down 15% quarter-over-quarter.
- 15 funds opened new MaxCyte positions in Q1 2024 and 12 closed out, a net change of +3 holders.
- The largest MaxCyte buyer in Q1 2024 was Chevy Chase Trust, an estimated $5.82M added.
- The largest MaxCyte seller in Q1 2024 was Morgan Stanley, an estimated $16.2M sold.
Based on aggregated 13F filings for Q1 2024.